HG-IMA (Raw data)

Background Ischemia and associated hypoxemia-induced oxidative stress play an important role in the pathogenesis of hyperemesis gravidarum. Objective The aim of this study was to investigate the role of ischemia-modified albumin in the prediction of hyperemesis gravidarum. Methods A prospective cohort study was conducted with 138 eligible participants with singleton pregnancies who had experienced hyperemesis gravidarum in previous pregnancies. Blood samples were taken from the participants ≤5th week of pregnancy, provided they had no symptoms of nausea and vomiting at that time. The samples were stored under appropriate conditions to be analyzed for ischemia-modified albumin in due course. All participants were then followed to determine whether they would develop hyperemesis gravidarum. Results ​Hyperemesis gravidarum occurred in 42 of the 138 participants (hyperemesis gravidarum group), while the remaining 96 participants did not develop hyperemesis gravidarum (control group). Baseline characteristics showed no significant differences. Ischemia-modified albumin levels were significantly higher in the hyperemesis gravidarum group (p<0.001). Ischemia-modified albumin levels did not correlate with body mass index or maternal age. Ischemia-modified albumin with a cut-off of >74.74 ng/mL (95% sensitivity, 67% specificity) had a discriminatory power with an AUC value of 0.791 (95% CI: 0.714-0.856; p<0.001) for predicting hyperemesis gravidarum. Conclusion Our results show an association between high ischemia-modified albumin levels in early pregnancy and an increased risk of hyperemesis gravidarum. ischemia-modified albumin can be used as a predictive tool for hyperemesis gravidarum.